Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kane Biotech, a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, has announced that the National Research Council Industrial Research Assistance Program has increased its contribution to the company by $150,000 bringing the total amount to $555,000.
Subscribe to our email newsletter
The additional contribution will be applied to the development of the company’s novel antibiofilm topical wound gel containing its patented DispersinB technology. DispersinB wound gel is being developed to treat chronic wound infections.
Gord Froehlich, president and CEO of Kane Biotech, said: “We are very pleased with the continued support from National Research Council Industrial Research Assistance Program (NRC-IRAP) for the development of DispersinB.
“We believe this is transformative technology for chronic wound infections, which are a serious and debilitating complication of vascular disease, diabetes and prolonged immobility, and that our technology can fill a huge unmet clinical need that costs the US healthcare system $20 billion per year.”